combination treatments, page-4

Hi Hoyland,

My point regarding where the technology goes is that it depends on what it is hitched to, more so than where BLT may sensibly focus its efforts (and money), as you illustrate with the examples.

Gene silencing is not unique to BLT, although I read they started it in mammals. Certainly good to see BLT was in on the ground floor and holds some patents / exclusive licences and farms out research permission.

There may be talk of takeover interest if one of the majors licensed to use BLT products in research finds some great success while employing them - but of course, lots of factors involved in such decisions and also generally no great desire of big pharma to take over minnows.

Why bother? They can still take them over when they cost $1 billion, or $10 billion, for that matter, if there is a quid in it, once it the issue has transformed from efficacy into manufacturing / marketing.

And thanks for the response, I am interested in where the technology is going, although even based on cursory research in the last couple of day, that appears to be anyone's guess, including the possibility of 'everywhere'.

Cheers